Raymond James & Associates Increases Stock Position in Teladoc Health, Inc. (NYSE:TDOC)

Raymond James & Associates boosted its stake in shares of Teladoc Health, Inc. (NYSE:TDOCGet Rating) by 0.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 223,502 shares of the health services provider’s stock after buying an additional 432 shares during the quarter. Raymond James & Associates owned 0.14% of Teladoc Health worth $5,666,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the stock. Vanguard Group Inc. boosted its stake in shares of Teladoc Health by 0.7% in the first quarter. Vanguard Group Inc. now owns 13,238,243 shares of the health services provider’s stock valued at $954,875,000 after purchasing an additional 98,181 shares during the period. Renaissance Technologies LLC boosted its stake in shares of Teladoc Health by 879.2% in the second quarter. Renaissance Technologies LLC now owns 4,475,319 shares of the health services provider’s stock valued at $148,625,000 after purchasing an additional 4,018,300 shares during the period. State of Michigan Retirement System boosted its stake in shares of Teladoc Health by 0.9% in the third quarter. State of Michigan Retirement System now owns 3,739,500 shares of the health services provider’s stock valued at $94,796,000 after purchasing an additional 33,131 shares during the period. Himension Capital Singapore PTE. LTD. boosted its stake in shares of Teladoc Health by 67.7% in the second quarter. Himension Capital Singapore PTE. LTD. now owns 2,167,552 shares of the health services provider’s stock valued at $71,984,000 after purchasing an additional 875,344 shares during the period. Finally, Northern Trust Corp boosted its stake in shares of Teladoc Health by 5.0% in the second quarter. Northern Trust Corp now owns 1,039,217 shares of the health services provider’s stock valued at $34,513,000 after purchasing an additional 49,855 shares during the period. Hedge funds and other institutional investors own 84.14% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on TDOC. Truist Financial decreased their price target on shares of Teladoc Health from $35.00 to $29.00 and set a “hold” rating for the company in a research note on Friday, October 21st. Deutsche Bank Aktiengesellschaft decreased their price target on shares of Teladoc Health from $34.00 to $31.00 and set a “hold” rating for the company in a research note on Tuesday, September 27th. Guggenheim upgraded shares of Teladoc Health from a “sell” rating to a “neutral” rating in a research note on Monday, October 24th. StockNews.com upgraded shares of Teladoc Health to a “sell” rating in a research note on Thursday, January 5th. Finally, Oppenheimer decreased their price target on shares of Teladoc Health from $55.00 to $45.00 in a research note on Thursday, October 27th. One equities research analyst has rated the stock with a sell rating, twenty-two have issued a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $48.21.

Insiders Place Their Bets

In other Teladoc Health news, insider Arnnon Geshuri sold 2,398 shares of the business’s stock in a transaction on Monday, November 28th. The shares were sold at an average price of $27.35, for a total transaction of $65,585.30. Following the sale, the insider now directly owns 74,317 shares in the company, valued at approximately $2,032,569.95. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 1.55% of the company’s stock.

Teladoc Health Stock Performance

NYSE:TDOC opened at $26.92 on Monday. The firm’s fifty day moving average price is $26.70 and its 200 day moving average price is $30.52. Teladoc Health, Inc. has a 1-year low of $21.60 and a 1-year high of $82.99. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.13 and a quick ratio of 2.99. The firm has a market cap of $4.36 billion, a price-to-earnings ratio of -0.44 and a beta of 0.98.

Teladoc Health (NYSE:TDOCGet Rating) last posted its quarterly earnings data on Wednesday, October 26th. The health services provider reported ($0.45) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.14. Teladoc Health had a negative net margin of 424.40% and a negative return on equity of 2.47%. The firm had revenue of $611.40 million for the quarter, compared to analyst estimates of $609.45 million. On average, sell-side analysts expect that Teladoc Health, Inc. will post -1.4 EPS for the current year.

Teladoc Health Profile

(Get Rating)

Teladoc Health, Inc provides virtual healthcare services in the United States and internationally. The company offers a portfolio of services and solutions covering non-urgent, episodic, chronic, and complicated medical conditions, including diabetes, hypertension, chronic kidney disease, cancer, congestive heart failure, and mental health conditions.

Read More

Want to see what other hedge funds are holding TDOC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teladoc Health, Inc. (NYSE:TDOCGet Rating).

Institutional Ownership by Quarter for Teladoc Health (NYSE:TDOC)

Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.